【摘要】 目的观察瑞舒伐他汀及辛伐他汀对心肌梗死患者血清Copeptin及基质金属蛋白酶-9水平的作用比较。方法选82例心肌梗死患者作为实验组,同期选取82例健康人为对照组。将82例心肌梗死患者随机分为2组①辛伐他汀组;②瑞舒伐他汀组。分别测定治疗前后血浆Copeptin、基质金属蛋白酶-9的浓度。结果急性心肌梗死患者血浆Copeptin、基质金属蛋白酶-9的测定值均高于对照组(P<0.01);瑞舒伐他汀组及辛伐他汀组治疗后Copeptin和基质金属蛋白酶-9的测定值均低于治疗前水平(P<0.01),且瑞舒伐他汀组与辛伐他汀组相比,更能降低患者Copeptin和基质金属蛋白酶-9水平,二者差异有统计学意义(P<0.01)。结论瑞舒伐他汀较辛伐他汀更能降低心肌梗死患者血清Copeptin及基质金属蛋白酶水平。更多还原

【Abstract】 Objective To compare serum Copeptin and matrix metalloproteinases-9 levels in patients of myocardial infarction with rosuvastatin and simvastatin. Methods 82 cases of myocardial infarction patients were randomly divided into 2 groups: ①simvastatin group; ②rosuvastatin group. The leves of℃reactive protein, matrix metalloproteinases 9 were measured despectively. Results The leves of plasma Copeptin,matrix metalloproteinases 9 determination value in patients with acute myocardial infarction were higher than that of control group ( P < 0. 01) ; Copeptin and matrix metalloproteinases 9 determination value in the rosuvastatin group and simvastatin group after the treatment of plasma were obviously lower than those before therapy level ( P < 0. 01) . And the level of Copeptin and matrix metalloproteinases 9 in therapy group were reduced. These all have statistics difference. Conclusion Rosuvastatin compared with simvastatin,can reduce the myocardial infarction patient blood serum Copeptin and matrix metalloproteinases levels.更多还原